Fertility Sparing Treatments in Endometrial Cancer Patients: The Potential Role of the New Molecular Classification
Abstract
:1. Introduction
2. Fertility Sparing Treatments
2.1. Patients Selection
2.2. Conservative Procedures
3. Molecular Classification and Its Impact on Fertility Outcomes
4. Obstetric Outcomes
5. Discussion
6. Conclusions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Duska, L.R.; Garrett, A.; Rueda, B.R.; Haas, J.; Chang, Y.; Fuller, A.F. Endometrial Cancer in Women 40 Years Old or Younger. Gynecol. Oncol. 2001, 83, 388–393. [Google Scholar] [CrossRef]
- Cancer Stat Facts: Uterine Cancer. Available online: https://seer.cancer.gov/statfacts/html/corp.html (accessed on 5 October 2021).
- Marcelo, G. Bioaerosol Size Effect in COVID-19 Transmission. 2020. Available online: https://www.preprints.org/manuscript/202004.0093/v1/download (accessed on 5 October 2021).
- Abu-Rustum, N.R.; Yashar, C.M.; Bradley, K.; Campos, S.M.; Chino, J.; Chon, H.S.; Chu, C.; Cohn, D.; Crispens, M.A.; Damast, S.; et al. NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021. J. Natl. Compr. Canc. Netw. 2021, 19, 888–895. [Google Scholar] [CrossRef]
- Park, J.-Y.; Kim, D.-Y.; Kim, J.-H.; Kim, Y.-M.; Kim, K.-R.; Kim, Y.-T.; Seong, S.J.; Kim, T.-J.; Kim, J.-W.; Kim, S.M.; et al. Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002). Eur. J. Cancer 2012, 49, 868–874. [Google Scholar] [CrossRef]
- Gunderson, C.C.; Fader, A.N.; Carson, K.A.; Bristow, R.E. Oncologic and Reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 Adenocarcinoma: A systematic review. Gynecol. Oncol. 2012, 125, 477–482. [Google Scholar] [CrossRef]
- Frumovitz, M.; Gershenson, D.M. Fertility-sparing therapy for young women with endometrial cancer. Expert Rev. Anticancer. Ther. 2006, 6, 27–32. [Google Scholar] [CrossRef]
- Concin, N.; Matias-Guiu, X.; Vergote, I.; Cibula, D.; Mirza, M.R.; Marnitz, S.; Ledermann, J.; Bosse, T.; Chargari, C.; Fagotti, A.; et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int. J. Gynecol. Cancer. 2021, 31, 12–39. [Google Scholar] [CrossRef] [PubMed]
- Chung, Y.S.; Woo, H.Y.; Lee, J.Y.; Park, E.; Nam, E.J.; Kim, S.; Kim, S.W.; Kim, Y.T. Mismatch repair status influences response to fertility-sparing treatment of endometrial cancer. Am. J. Obstet. Gynecol. 2021, 224, 370.e1–370.e13. [Google Scholar] [CrossRef]
- Lee, N.K.; Cheung, M.K.; Shin, J.Y.; Husain, A.; Teng, A.; Husain, N.N.; Berek, J.S.; Kapp, D.S.; Osann, K.; Chan, J.K. Prognostic factors for uterine cancer in reproductive-aged women. Obstet. Gynecol. 2007, 109, 655–662. [Google Scholar] [CrossRef] [PubMed]
- Evans-Metcalf, E.R.; Brooks, S.E.; Reale, F.R.; Baker, S.P. Profile of women 45 years of age and younger with endometrial cancer. Obstet. Gynecol. 1998, 91, 349–354. [Google Scholar] [CrossRef]
- Gunderson, C.C.; Java, J.; Moore, K.N.; Walker, J.L. The impact of obesity on surgical staging, complications, and survival with uterine cancer: A Gynecologic Oncology Group LAP2 ancillary data study. Gynecol. Oncol. 2014, 133, 23–27. [Google Scholar] [CrossRef]
- Obermair, A.; Brennan, D.J.; Baxter, E.; Armes, J.E.; Gebski, V.; Janda, M. Surgical safety and personal costs in morbidly obese, multimorbid patients diagnosed with early-stage endometrial cancer having a hysterectomy. Gynecol. Oncol. Res. Pract. 2016, 3, 1. [Google Scholar] [CrossRef] [Green Version]
- Gallotta, V.; Conte, C.; D’Indinosante, M.; Federico, A.; Biscione, A.; Vizzielli, G.; Bottoni, C.; Carbone, M.V.; Legge, F.; Uccella, S.; et al. Robotic Surgery in Elderly and Very Elderly Gynecologic Cancer Patients. J. Minim. Invasive Gynecol. 2018, 25, 872–877. [Google Scholar] [CrossRef]
- Mourits, M.J.; Bijen, C.B.; Arts, H.J.; ter Brugge, H.G.; van der Sijde, R.; Paulsen, L.; Wijma, J.; Bongers, M.Y.; Post, W.J.; van der Zee, A.G.; et al. Safety of laparoscopy versus laparotomy in early-stage endometrial cancer: A randomised trial. Lancet. Oncol. 2010, 11, 763–771. [Google Scholar] [CrossRef] [Green Version]
- Corrado, G.; Vizza, E.; Perrone, A.M.; Mereu, L.; Cela, V.; Legge, F.; Hilaris, G.; Pasciuto, T.; D’Indinosante., M.; La Fera, E.; et al. Comparison Between Laparoscopic and Robotic Surgery in Elderly Patients With Endometrial Cancer: A Retrospective Multicentric Study. Front Oncol. 2021, 11, 724886. [Google Scholar] [CrossRef]
- Janda, M.; Gebski, V.; Davies, L.C.; Forder, P.; Brand, A.; Hogg, R.; Jobling, T.W.; Land, R.; Manolitsas, T.; Nascimento, M.; et al. Effect of total laparoscopic hysterectomy vs. total abdominal hysterectomy on disease-free survival among women with stage I endometrial cancer: A randomized clinical trial. JAMA 2017, 317, 1224–1233. [Google Scholar] [CrossRef] [Green Version]
- Walker, J.L.; Piedmonte, M.R.; Spirtos, N.M.; Eisenkop, S.M.; Schlaerth, J.B.; Mannel, R.S.; Spiegel, G.; Barakat, R.; Pearl, M.L.; Sharma, S.K. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. J. Clin. Oncol. 2009, 27, 5331–5336. [Google Scholar] [CrossRef] [PubMed]
- Asher, R.; Obermair, A.; Janda, M.; Gebski, V. Disease-free and survival outcomes for total laparoscopic hysterectomy compared with total abdominal hysterectomy in early-stage endometrial carcinoma: A meta-analysis. Int. J. Gynecol. Cancer 2018, 28, 529–538. [Google Scholar] [CrossRef]
- Kondalsamy-Chennakesavan, S.; Janda, M.; Gebski, V.; Baker, J.; Brand, A.; Hogg, R.; Jobling, T.W.; Land, R.; Manolitsas, T.; Nascimento, M.; et al. Risk factors to predict the incidence of surgical adverse events fol-lowing open or laparoscopic surgery for apparent early stage endometrial cancer: Results from a randomised controlled trial. Eur. J. Cancer 2012, 48, 2155–2162. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hawkes, A.; Quinn, M.; Gebski, V.; Armes, J.; Brennan, D.; Janda, M.; Obermair, A. Improving treatment for obese women with early stage cancer of the uterus: Rationale and design of the levonorgestrel intrauterine device±Metformin±weight loss in endometrial cancer (feMME) trial. Contemp. Clin. Trials 2014, 39, 14–21. [Google Scholar] [CrossRef] [Green Version]
- Leitao, M.M., Jr.; Kehoe, S.; Barakat, R.R.; Alektiar, K.; Gattoc, L.P.; Rabbitt, C.; Chi, D.S.; Soslow, R.A.; Abu-Rustum, N.R. Comparison of D&C and office endometrial biopsy accuracy in patients with FIGO grade 1 endometrial adenocarcinoma. Gynecol. Oncol. 2009, 113, 105–108. [Google Scholar]
- Kaku, T.; Yoshikawa, H.; Tsuda, H.; Sakamoto, A.; Fukunaga, M.; Kuwabara, Y.; Hataeg, M.; Kodama, S.; Kuzuya, K.; Sato, S.; et al. Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: Central pathologic review and treatment outcome. Cancer Lett. 2001, 167, 39–48. [Google Scholar] [CrossRef]
- Zaino, R.J.; Kauderer, J.; Trimble, C.L.; Silverberg, S.G.; Curtin, J.P.; Lim, P.C.; Gallup, D.G. Reproducibility of the diagnosis of atypical endometrial hyperplasia: A Gynecologic Oncology Group study. Cancer 2006, 106, 804–811. [Google Scholar] [CrossRef] [PubMed]
- Win, A.K.; Reece, J.C.; Ryan, S. Family history and risk of endometrial cancer: A systematic review and meta-analysis. Obstet. Gynecol. 2015, 125, 89–98. [Google Scholar] [CrossRef]
- Johnatty, S.E.; Tan, Y.; Buchanan, D.D.; Bowman, M.; Walters, R.J.; Obermair, A.; Quinn, M.A.; Blomfield, P.B.; Brand, A.; Leung, Y.; et al. Family history of cancer predicts endometrial cancer risk independently of Lynch Syndrome: Implications for genetic counselling. Gynecol. Oncol. 2017, 147, 381–387. [Google Scholar] [CrossRef]
- Sehgal, R.; Sheahan, K.; O’Connell, P.R.; Hanly, A.M.; Martin, S.T.; Winter, D.C. Lynch Syndrome: An Updated Review. Genes 2014, 5, 497–507. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bonadona, V.; Bonaïti, B.; Olschwang, S.; Grandjouan, S.; Huiart, L.; Longy, M.; Guimbaud, R.; Buecher, B.; Bignon, Y.-J.; Caron, O.; et al. Cancer Risks Associated With Germline Mutations in MLH1, MSH2, and MSH6 Genes in Lynch Syndrome. JAMA 2011, 305, 2304–2310. [Google Scholar] [CrossRef] [PubMed]
- Rodolakis, A.; Biliatis, I.; Morice, P.; Reed, N.; Mangler, M.; Kesic, V.; Denschlag, D. European Society of Gynecological Oncology Task Force for Fertility Preservation: Clinical Recommendations for Fertility-Sparing Management in Young Endometrial Cancer Patients. Int. J. Gynecol. Cancer 2015, 25, 1258–1265. [Google Scholar] [CrossRef]
- Koskas, M.; Uzan, J.; Luton, D.; Rouzier, R.; Daraï, E. Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: Systematic review and meta-analysis. Fertil. Steril. 2014, 101, 785–794.e3. [Google Scholar] [CrossRef]
- Ramirez, P.T.; Frumovitz, M.; Bodurka, D.; Sun, C.C.; Levenback, C. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: A literature review. Gynecol. Oncol. 2004, 95, 133–138. [Google Scholar] [CrossRef]
- Van Heertum, K.; Liu, J. Differential effects of progestogens used for menopausal hormone therapy. Clin. Obstet. Gynecol. 2018, 61, 454–462. [Google Scholar] [CrossRef] [PubMed]
- Thigpen, J.T.; Brady, M.F.; Alvarez, R.D.; Adelson, M.D.; Homesley, H.D.; Manetta, A.; Soper, J.T.; Given, F.T. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: A dose-response study by the Gynecologic Oncology Group. J. Clin. Oncol. 1999, 17, 1736–1744. [Google Scholar] [CrossRef] [PubMed]
- Yuk, J.-S.; Song, J.Y.; Lee, J.H.; Park, W.I.; Ahn, H.S.; Kim, H.J. Levonorgestrel-Releasing Intrauterine Systems Versus Oral Cyclic Medroxyprogesterone Acetate in Endometrial Hyperplasia Therapy: A Meta-Analysis. Ann. Surg. Oncol. 2016, 24, 1322–1329. [Google Scholar] [CrossRef]
- Kim, M.K.; Seong, S.J.; Lee, T.S.; Kim, J.W.; Nam, B.H.; Hong, S.R.; Suh, K.S. Treatment with Medroxyprogesterone Acetate Plus Levonorgestrel-releasing Intrauterine System for Early-stage Endometrial Cancer in Young Women: Single-arm, Prospective Multicenter Study: Korean Gynecologic Oncology Group Study (KGOG2009). Jpn. J. Clin. Oncol. 2012, 42, 1215–1218. [Google Scholar] [CrossRef] [Green Version]
- Alonso, S.; Castellanos, T.; Lapuente, F.; Chiva, L. Hysteroscopic surgery for conservative management in endometrial cancer: A review of the literature. Ecancermedicalscience 2015, 9. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Masciullo, V.; Trivellizzi, N.; Zannoni, G.; Catena, U.; Moroni, R.; Fanfani, F.; Scambia, G. Prognostic impact of hysteroscopic resection of endometrial atypical hyperplasia-endometrioid intraepithelial neoplasia and early-stage cancer in combination with megestrol acetate. Am. J. Obstet. Gynecol. 2021, 224, 408–410. [Google Scholar] [CrossRef]
- Kim, M.K.; Seong, S.J.; Song, T.; Yoon, B.S.; Jun, H.S.; Lee, G.H.; Lee, Y.H. Comparison of dilatation & curettage and endometrial aspiration biopsy accuracy in patients treated with high-dose oral progestin plus levonorgestrel intrauterine system for early-stage endometrial cancer. Gynecol. Oncol. 2013, 130, 470–473. [Google Scholar] [CrossRef]
- Kandoth, C.; Schultz, N.; Cherniack, A.D.; Akbani, R.; Liu, Y.; Shen, H.; Robertson, A.G.; Pashtan, I.; Shen, R.; Benz, C.C.; et al. Integrated Genomic Characterization of Endometrial Carcinoma. Nature 2013, 497, 67–73. [Google Scholar]
- Ritterhouse, L.L.; Howitt, B.E. Molecular Pathology. Surg. Pathol. Clin. 2016, 9, 405–426. [Google Scholar] [CrossRef] [PubMed]
- Oldfield, L.E.; Li, T.; Tone, A.; Aronson, M.; Edwards, M.; Holter, S.; Quevedo, R.; Van de Laar, E.; Lerner-Ellis, J.; Pollett, A.; et al. An Integrative DNA Sequencing and Methylation Panel to Assess Mismatch Repair Deficiency. J. Mol. Diagn. 2021, 23, 242–252. [Google Scholar] [CrossRef] [PubMed]
- Baxter, E.; Brennan, D.J.; McAlpine, J.N.; Mueller, J.J.; Amant, F.; Van Gent, M.D.J.M.; Huntsman, D.G.; Coleman, R.L.; Westin, S.N.; Yates, M.S.; et al. Improving response to progestin treatment of low-grade endometrial cancer. Int. J. Gynecol. Cancer 2020, 30, 1811–1823. [Google Scholar] [CrossRef] [PubMed]
- Travaglino, A.; Raffone, A.; Saccone, G.; Insabato, L.; Mollo, A.; De Placido, G.; Zullo, F. Immunohistochemical predictive markers of response to conservative treatment of endometrial hyperplasia and early endometrial cancer: A systematic review. Acta Obstet. Gynecol. Scand. 2019, 98, 1086–1099. [Google Scholar] [CrossRef]
- Makabe, T.; Arai, E.; Hirano, T.; Ito, N.; Fukamachi, Y.; Takahashi, Y.; Hirasawa, A.; Yamagami, W.; Susumu, N.; Aoki, D.; et al. Genome-wide DNA methylation profile of early-onset endometrial cancer: Its correlation with genetic aberrations and comparison with late-onset endometrial cancer. Carcinogenesis 2019, 40, 611–623. [Google Scholar] [CrossRef] [PubMed]
- Hu, T.W.Y.; Li, L.; Yang, E.; Nie, D.; Li, Z.Y. Molecular expression characteristics confirm the malignancy concealed by mor- phological alterations in endometrial cancer after fertility-preserving treatment. Arch. Gynecol. Obstet. 2019, 299, 1673–1682. [Google Scholar] [CrossRef] [PubMed]
- Vermij, L.; Smit, V.; Nout, R.; Bosse, T. Incorporation of molecular characteristics into endometrial cancer management. Histopathology 2019, 76, 52–63. [Google Scholar] [CrossRef]
- Myers, A.; Barry, W.T.; Hirsch, M.S.; Matulonis, U.; Lee, L. β-Catenin mutations in recurrent FIGO IA grade I endometrioid endometrial cancers. Gynecol. Oncol. 2014, 134, 426–427. [Google Scholar] [CrossRef]
- Kurnit, K.; Kim, G.N.; Fellman, B.M.; Urbauer, D.L.; Mills, G.; Zhang, W.; Broaddus, R.R. CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence. Mod. Pathol. 2017, 30, 1032–1041. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Arend, R.C.; Jones, B.A.; Martinez, A.; Goodfellow, P. Endometrial cancer: Molecular markers and management of advanced stage disease. Gynecol. Oncol. 2018, 150, 569–580. [Google Scholar] [CrossRef]
- Bosse, T.; Nout, R.A.; McAlpine, J.N.; McConechy, M.K.; Britton, H.; Hussein, Y.R.; Gonzalez, C.; Ganesan, R.; Steele, J.C.; Harrison, B.T.; et al. Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups. Am. J. Surg. Pathol. 2018, 42, 561–568. [Google Scholar] [CrossRef]
- Floyd, J.L.; Campbell, S.; Rauh-Hain, J.A.; Woodard, T. Fertility preservation in women with early-stage gynecologic cancer: Optimizing oncologic and reproductive outcomes. Int. J. Gynecol. Cancer. 2021, 31, 345–351. [Google Scholar] [CrossRef]
- Trojano, G.; Olivieri, C.; Tinelli, R.; Damiani, G.R.; Pellegrino, A.; Cicinelli, E. Conservative treatment in early stage endometrial cancer: A review. Acta Biomed. 2019, 90, 405–410. [Google Scholar] [CrossRef] [PubMed]
- Letourneau, J.M.; Ebbel, E.E.; Katz, P.P.; Katz, A.; Ai, W.Z.; Chien, A.J.; Melisko, M.E.; Cedars, M.I.; Rosen, M.P. Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer. Cancer 2011, 118, 1710–1717. [Google Scholar] [CrossRef] [Green Version]
- Shah, J.S.; Jooya, N.D.; Ramirez, P.T.; Fleming, N.D.; Frumovitz, M. Reproductive counseling and pregnancy outcomes after radical trachelectomy for early stage cervical cancer. J. Gynecol. Oncol. 2019, 30, e45. [Google Scholar] [CrossRef]
- Crafton, S.; Nekkanti, S.; Lynch, C.; Cohn, D.E.; Fowler, J.M.; Copeland, L.J.; O’Malley, D.M.; Salani, R.; Backes, F.J.; Eisenhauer, E.L. Documentation of Pregnancy Risk Assessment and Pregnancy Among Women Presenting for Gynecologic Oncology Consultation. Int. J. Gynecol. Cancer 2016, 26, 35–42. [Google Scholar] [CrossRef] [PubMed]
- Garzon, S.; Uccella, S.; Zorzato, P.C.; Bosco, M.; Franchi, M.; Student, V.; Mariani, A. Fertility-sparing management for endometrial cancer: Review of literature. Minerva Med. 2021, 112, 55–69. [Google Scholar] [CrossRef]
- Zhang, Z.; Huang, H.; Feng, F.; Wang, J.; Cheng, N. A pilot study of gonadotropin-releasing hormone agonist combined with aromatase inhibitor as fertility-sparing treatment in obese patients with endometrial cancer. J. Gynecol. Oncol. 2019, 30, e61. [Google Scholar] [CrossRef] [PubMed]
- Fujimoto, A.; Ichinose, M.; Harada, M.; Hirata, T.; Osuga, Y.; Fujii, T. The outcome of infertility treatment in patients undergoing assisted reproductive technology after conservative therapy for endometrial cancer. J. Assist. Reprod. Genet. 2014, 31, 1189–1194. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yang, B.; Xie, L.; Zhang, H.; Zhu, Q.; Du, Y.; Luo, X.; Chen, X. Insulin resistance and overweight prolonged fertility-sparing treatment duration in endometrial atypical hyperplasia patients. J. Gynecol. Oncol. 2018, 29, e35. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chao, A.S.; Chao, A.; Wang, C.J.; Lai, C.H.; Wang, H.S. Obstetric outcomes of pregnancy after conservative treatment of endometrial cancer: Case series and literature review. Taiwan J. Obstet. Gynecol. 2011, 50, 62–66. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, Y.; Zhou, R.; Wang, H.; Liu, H.; Wang, J. Impact of treatment duration in fertility-preserving management of endometrial cancer or atypical endometrial hyperplasia. Int. J. Gynecol. Cancer 2019, 29, 699–704. [Google Scholar] [CrossRef] [PubMed]
- Gallos, I.D.; Yap, J.; Rajkhowa, M.; Luesley, D.M.; Coomarasamy, A.; Gupta, J.K. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: A systematic review and metaanalysis. Am. J. Obstet. Gynecol. 2012, 207, 266.e1–266.e12. [Google Scholar] [CrossRef]
- Zhou, R.; Yang, Y.; Lu, Q.; Wang, J.; Miao, Y.; Wang, S.; Wang, Z.; Zhao, C.; Wei, L. Prognostic factors of oncological and reproductive outcomes in fertility-sparing treatment of complex atypical hyperplasia and low-grade endometrial cancer using oral progestin in Chinese patients. Gynecol. Oncol. 2015, 139, 424–428. [Google Scholar] [CrossRef]
- Bokhman, J.V. Two pathogenetic types of endometrial carcinoma. Gynecol. Oncol. 1983, 15, 10–17. [Google Scholar] [CrossRef]
- Dondi, G.; Coluccelli, S.; De Leo, A.; Ferrari, S.; Gruppioni, E.; Bovicelli, A.; Godino, L.; Coadă, C.A.; Morganti, A.G.; Giordano, A.; et al. An Analysis of Clinical, Surgical, Pathological and Molecular Characteristics of Endometrial Cancer According to Mismatch Repair Status. A Multidisciplinary Approach. Int. J. Mol. Sci. 2020, 21, 7188. [Google Scholar] [CrossRef] [PubMed]
- Obermair, A.; Baxter, E.; Brennan, D.J.; McAlpine, J.N.; Muellerer, J.J.; Amant, F.; van Gent, M.D.J.M.; Coleman, R.L.; Westin, S.N.; Yates, M.S.; et al. Fertility-sparing treatment in early endometrial cancer: Current state and future strategies. Obstet. Gynecol. Sci. 2020, 63, 417–431. [Google Scholar] [CrossRef]
- Colombo, N.; Creutzberg, C.; Amant, F.; Bosse, T.; González-Martín, A.; Ledermann, J.; Marth, C.; Nout, R.; Querleu, D.; Mirza, M.R.; et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up. Int. J. Gynecol. Cancer 2016, 26, 2–30. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Piergentili, R.; Zaami, S.; Cavaliere, A.; Signore, F.; Scambia, G.; Mattei, A.; Marinelli, E.; Gulia, C.; Perelli, F. Non-Coding RNAs as Prognostic Markers for Endometrial Cancer. Int. J. Mol. Sci. 2021, 22, 3151. [Google Scholar] [CrossRef] [PubMed]
- Vallone, C.; Rigon, G.; Gulia, C.; Baffa, A.; Votino, R.; Morosetti, G.; Zaami, S.; Briganti, V.; Catania, F.; Gaffi, M.; et al. Non-Coding RNAs and Endometrial Cancer. Genes 2018, 9, 187. [Google Scholar] [CrossRef] [Green Version]
- Cavaliere, A.; Perelli, F.; Zaami, S.; Piergentili, R.; Mattei, A.; Vizzielli, G.; Scambia, G.; Straface, G.; Restaino, S.; Signore, F. Towards Personalized Medicine: Non-Coding RNAs and Endometrial Cancer. Healthcare 2021, 9, 965. [Google Scholar] [CrossRef] [PubMed]
- Nero, C.; Ciccarone, F.; Pietragalla, A.; Duranti, S.; Daniele, G.; Scambia, G.; Lorusso, D. Adjuvant Treatment Recommendations in Early-Stage Endometrial Cancer: What Changes With the Introduction of The Integrated Molecular-Based Risk Assessment. Front. Oncol. 2021, 11. [Google Scholar] [CrossRef]
- ESHRE Guideline Group on Female Fertility Preservation; Anderson, R.A.; Amant, F.; Braat, D.; D’Angelo, A.; Chuva de Sousa Lopes, S.M.; Demeestere, I.; Dwek, S.; Frith, L.; Lambertini, M.; et al. ESHRE Guideline: Female Fertility Preservation. Available online: https://pubmed.ncbi.nlm.nih.gov/33225079/ (accessed on 5 October 2021).
- La Rosa, V.L.; Garzon, S.; Gullo, G.; Fichera, M.; Sisti, G.; Gallo, P.; Riemma, G.; Schiattarella, A.; La Rosa, V. Fertility preservation in women affected by gynaecological cancer: The importance of an integrated gynaecological and psychological approach. Ecancermedicalscience 2020, 14, 1035. [Google Scholar] [CrossRef] [PubMed]
- Britton, H.; Huang, L.; Lum, A.; Leung, S.; Shum, K.; Kale, M.; Burleigh, A.; Senz, J.; Yang, W.; McConechy, M.; et al. Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma. Gynecol. Oncol. 2019, 153, 487–495. [Google Scholar] [CrossRef] [PubMed]
- Falcone, F.; Normanno, N.; Losito, N.S.; Scognamiglio, G.; Esposito Abate, R.; Chicchinelli, N.; Casella, G.; Laurelli, G.; Scaffa, C.; Greggi, S. Application of the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) to patients conservatively treated: Outcomes from an institutional series. Eur. J. Obstet. Gynecol. Reprod. Biol. 2019, 240, 220–225. [Google Scholar] [CrossRef] [PubMed]
- Berstein, L.M.; Iyevleva, A.G.; Ivantsov, A.O.; Vasilyev, D.A.; Poroshina, T.E.; Berlev, I.V. Endocrinology of obese and nonobese endometrial cancer patients: Is there role of tumor molecular-biological type? Future Oncol. 2019, 15, 1335–1346. [Google Scholar] [CrossRef] [PubMed]
- Gan, Q.; Crumley, S.; Broaddus, R.R. Molecular Modifiers of Hormone Receptor Action: Decreased Androgen Receptor Expression in Mismatch Repair Deficient Endometrial Endometrioid Adenocarcinoma. Int. J. Gynecol. Pathol. 2019, 38, 44–51. [Google Scholar] [CrossRef]
- Garg, K.; Shih, K.; Barakat, R.; Zhou, Q.; Iasonos, A.; Soslow, R.A. Endometrial Carcinomas in Women Aged 40 Years and Younger: Tumors Associated With Loss of DNA Mismatch Repair Proteins Comprise a Distinct Clinicopathologic Subset. Am. J. Surg. Pathol. 2009, 33, 1869–1877. [Google Scholar] [CrossRef]
- Raffone, A.; Catena, U.; Travaglino, A.; Masciullo, V.; Spadola, S.; Della Corte, L.; Piermattei, A.; Insabato, L.; Zannoni, G.F.; Scambia, G.; et al. Mismatch repair-deficiency specifically predicts recurrence of atypical endometrial hyperplasia and early endometrial carcinoma after conservative treatment: A multi-center study. Gynecol. Oncol. 2021, 161, 795–801. [Google Scholar] [CrossRef] [PubMed]
- Stelloo, E.; Nout, R.A.; Naves, L.C.; ter Haar, N.T.; Creutzberg, C.L.; Smit, V.T.; Bosse, T. High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma. Gynecol. Oncol. 2014, 133, 197–204. [Google Scholar] [CrossRef]
- Tonacchera, M.; Chiovato, L.; Bartalena, L.; Cavaliere, A.F.; Vitti, P. Treatment of Graves’ hyperthyroidism with thionamides: A position paper on indications and safety in pregnancy. J. Endocrinol. Investig. 2019, 43, 257–265. [Google Scholar] [CrossRef]
- Rigon, G.; Vallone, C.; Lucantoni, V.; Signore, F. Maternal Factors Pre- and During Delivery Contribute to Gut Microbiota Shaping in Newborns. Front. Cell. Infect. Microbiol. 2012, 2, 93. [Google Scholar] [CrossRef] [Green Version]
- De Vincenzo, R.; Tortorella, L.; Ricci, C.; Cavaliere, A.F.; Zannoni, G.F.; Cefalo, M.G.; Scambia, G.; Fagotti, A. Locally advanced cervical cancer complicating pregnancy: A case of competing risks from the Catholic University of the Sacred Heart in Rome. Gynecol. Oncol. 2018, 150, 398–405. [Google Scholar] [CrossRef] [PubMed]
Risk Category | Risk Factor Status |
---|---|
Low | FIGO Stage I Endometrioid histotype grade 1–2 <50% myometrial invasion LVSI negative |
Intermediate | FIGO Stage I Endometrioid histotype grade 1–2 ≥50% myometrial invasion LVSI negative |
High-intermediate | FIGO Stage I Endometrioid histotype grade 3 <50% myometrial invasion regardless of LVSI status or FIGO Stage I Endometrioid histotype grade 1–2 LVSI unequivocally positive regardless of depth of invasion |
High | FIGO Stage I Endometrioid histotype grade 3 ≥50% myometrial invasion regardless of LVSI status or FIGO Stage II or FIGO Stage III Endometrioid histotype no residual disease or Non-endometrioid histotype (Serous, clear cell, undifferentiated carcinoma or carcinosarcoma) |
Advanced | FIGO Stage III residual disease or Stage IVA |
Metastatic | FIGO Stage IVB |
(1) |
Risk Category | Risk Factor Status |
---|---|
Low | FIGO Stage I–II POLEmut no residual disease or FIGO stage IA MMRd/NSMP Endometrioid histotype grade 1–2 LVSI negative or focal |
Intermediate | FIGO Stage IB Endometrioid histotype grade 1–2 LVSI negative or focal or FIGO stage IA MMRd/NSMP Endometrioid histotype grade 3 LVSI negative or focal or FIGO stage IA p53abn and/or non-endometrioid histotype (Serous, clear cell, undifferentiated carcinoma or carcinosarcoma) |
High-intermediate | FIGO Stage I MMRd/NSMP substantial LVSI regrdless of grade and depth of invasion or FIGO Stage IB MMRd/NSMP Endometrioid histotype grade 3 regardless of LVSI status or FIGO Stage II MMRd/NSMP Endometrioid histotype |
High | FIGO Stage III–IVA MMRd/NSMP Endometrioid histotype no residual disease or FIGO Stage I-IVA p53abn no residual disease or FIGO Stage I–IVA MMRd/NSMP serous, undifferentiated carcinoma or carcinosarcoma with myometrial invasion no residual disease |
Advanced metastatic | FIGO Stage III–IVA residual disease any molecular type or Stage IVB any molecular type |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Cavaliere, A.F.; Perelli, F.; Zaami, S.; D’Indinosante, M.; Turrini, I.; Giusti, M.; Gullo, G.; Vizzielli, G.; Mattei, A.; Scambia, G.; et al. Fertility Sparing Treatments in Endometrial Cancer Patients: The Potential Role of the New Molecular Classification. Int. J. Mol. Sci. 2021, 22, 12248. https://doi.org/10.3390/ijms222212248
Cavaliere AF, Perelli F, Zaami S, D’Indinosante M, Turrini I, Giusti M, Gullo G, Vizzielli G, Mattei A, Scambia G, et al. Fertility Sparing Treatments in Endometrial Cancer Patients: The Potential Role of the New Molecular Classification. International Journal of Molecular Sciences. 2021; 22(22):12248. https://doi.org/10.3390/ijms222212248
Chicago/Turabian StyleCavaliere, Anna Franca, Federica Perelli, Simona Zaami, Marco D’Indinosante, Irene Turrini, Marco Giusti, Giuseppe Gullo, Giuseppe Vizzielli, Alberto Mattei, Giovanni Scambia, and et al. 2021. "Fertility Sparing Treatments in Endometrial Cancer Patients: The Potential Role of the New Molecular Classification" International Journal of Molecular Sciences 22, no. 22: 12248. https://doi.org/10.3390/ijms222212248